Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s disease
- 31 July 2004
- journal article
- abstracts
- Published by Elsevier in Gastroenterology
- Vol. 127 (1) , 332
- https://doi.org/10.1053/j.gastro.2004.05.011
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: